NeoGenomics, Inc. (NEO) Fair Value 2026

NEO · Diagnostics & Research ·

By CirclFi Research Team · Data from SEC EDGAR, FRED & GDELT

Quality Score

6.6 /10

32 fundamental signals · 2 models active

Value Trap Risk

LOW (27/100)

Quick Summary — As of 2026-08-27, NeoGenomics, Inc. (NEO) trades at $18.64, versus a $15.30 median fair value across its 2 active models — 17.9% below the current price. QOC: 6.6/10. Value Trap Risk: 27/100 (LOW). 2/13 models active.

Key Facts

Ticker
NEO
Price
$18.64
Quality Score
6.6/10
Value Trap Risk
27/100
Models Active
2/13
Last Updated
Strength: 2 independent models provide multi-angle coverage
Risk: Majority of models suggest overvaluation

Is NeoGenomics, Inc. (NEO) Undervalued or Overvalued in 2026?

According to CirclFi’s 2-model valuation engine, NeoGenomics, Inc. (NEO) appears overvalued as of : the median of 2 independent fair value estimates is $15.30, 17.9% below the current price of $18.64. Estimates range from $13.58 to $17.03. NEO scores 6.6/10 on fundamental quality and 27/100 on value-trap risk.

For context, the median US equity CirclFi rates trades at an implied -23.7% versus its own 13-model consensus, across 3,801 rated companies as of 2026-08-27. NEO’s -17.9% gap is narrower than that market norm, and the Diagnostics & Research sector median is -54.1%. Full market index →

This verdict compares price to intrinsic value only — it is not a buy or sell rating. For the decision case (bull vs bear arguments, risk factors, peers), read Should You Buy NeoGenomics, Inc. Stock in 2026? →

What Fair Value Does Each Model Give NEO?

2 Intrinsic Value Models vs. Current Price ($18.64)

Core Models (Unlocked)
Model Fair Value Upside
Relative · High Conviction
 $13.58 -27.2%
Relative · Low Conviction
 $17.03 -8.6%

All Models Active

All 2 models are displayed above.

What Is NeoGenomics, Inc. (NEO) Worth in 2026?

According to the CirclFi Deep Alpha Valuation Engine, NeoGenomics, Inc.'s intrinsic value is estimated at $15.30. Trading at its current price of $18.64, the valuation engine raises significant caution: 2 of 2 models flag downside risk, projecting a median implied return of -17.9%.

What Do the Models Say About NEO?

2 of 13 models are currently active for NEO. All 2 active models suggest the stock trades above fair value. Taken together, their median fair value for NEO is $15.30 — the figure CirclFi publishes as this stock's fair value. See which stocks rank higher →

How Does NEO Rank in Diagnostics & Research?

Among 52 Diagnostics & Research stocks, NEO ranks #29 by Quality of Company score. CirclFi's QOC score of 6.6/10 evaluates 32 fundamental signals. A score of 6.6 indicates above-average quality.

The Diagnostics & Research sector introduces analytical considerations specific to healthcare company businesses. For NeoGenomics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.

Is NEO a Value Trap?

CirclFi's Value Trap algorithm assigns NEO a score of 27/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →

Multi-Model Methodology

2 of 13 models are active for NeoGenomics, Inc.. Limited activation may indicate insufficient history. Each model applies a fundamentally different valuation philosophy. See the complete methodology →

According to the CirclFi Quality of Company (QOC) framework, NeoGenomics, Inc. earns a quality score of 6.6/10. This respectable rating reflects the company's standing across 32 fundamental signals spanning profitability, growth consistency, balance sheet strength, and capital allocation efficiency.

Models cluster within a tight range (+18.5% spread), increasing conviction. Browse all stocks with 13-model coverage →

Data Sources & Confidence

Every NEO valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →

Across NEO's 2 active models, average confidence is 29%. Lower confidence may reflect limited history or high volatility.

CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →

This analysis is produced by the CirclFi Valuation Engine using quantitative models applied to SEC EDGAR filings, public market feeds, and FRED macroeconomic indicators. It is not financial advice.

Read the full investment analysis: Should You Buy NeoGenomics, Inc. Stock in 2026? →

Bull case, bear case, risk factors & peer comparison — updated daily

Which Similar Diagnostics & Research Stocks Should You Also Analyze?

11 related Diagnostics & Research stocks with 13-model coverage

RDNTRadNet, Inc.QOC 6.7MYGNMyriad Genetics, Inc.QOC 6.6XGNExagen Inc.QOC 6.7BNRBurning Rock Biotech LimitedQOC 6.5PRPOPrecipio, Inc.QOC 6.7WGSGeneDx Holdings Corp.QOC 6.4BIAFbioAffinity Technologies, Inc.QOC 5.0AAgilent Technologies, Inc.QOC 9.1LDDDLongduoduo Company LimitedQOC 7.5IDXXIDEXX Laboratories, Inc.QOC 9.5MEDPMedpace Holdings, Inc.QOC 9.3

Read investment analysis: RDNT · MYGN · XGN · BNR · PRPO · WGS · BIAF · A · LDDD · IDXX · MEDP

Which Other Stocks Have a Similar Quality Score to NEO?

7 companies across all industries closest to NEO’s Quality of Company score of 6.6/10.

GTNGray Media, Inc.QOC 6.6NCDLNuveen Churchill Direct Lending Corp.QOC 6.6CVLGCovenant Logistics Group, Inc.QOC 6.6ABCLAbCellera Biologics Inc.QOC 6.6CLARClarus CorporationQOC 6.6MLPMaui Land & Pineapple Company, Inc.QOC 6.6NVDANVIDIA CorporationQOC 10.0

Read investment analysis: GTN · NCDL · CVLG · ABCL · CLAR · MLP · NVDA

What Else Do Investors Ask About NeoGenomics, Inc.’s Valuation?

What is NeoGenomics, Inc.'s intrinsic value in 2026?

CirclFi puts NeoGenomics, Inc. (NEO)'s intrinsic value at $15.30 — the median of 2 independent model estimates as of 2026-08-27, ranging from $13.58 to $17.03. The Quality of Company score is 6.6/10 across 32 fundamental signals. All models use SEC EDGAR filings updated daily. See our methodology page for how each model works.

Is NEO overvalued or undervalued right now?

At $18.64, 0 of 2 active models suggest NEO may be undervalued, while 2 indicate potential overvaluation. The median of all 2 fair value estimates is $15.30, 17.9% below the current price of $18.64 — a consensus view that NEO is overvalued. The assessment depends on which methodology best fits NeoGenomics, Inc.'s business model in Diagnostics & Research.

What does a Quality of Company score of 6.6 mean for NEO?

NeoGenomics, Inc.'s QOC of 6.6/10 reflects 32 fundamental signals: profitability margins, revenue growth consistency, balance sheet leverage, free cash flow generation, and capital allocation efficiency. Scores between 5-7 reflect moderate fundamentals with areas for improvement.

How many valuation models does CirclFi run on NEO?

CirclFi analyzes NEO with 13 institutional-grade models daily: Bayesian DCF (Monte Carlo + jump-diffusion), EPV (Greenwald zero-growth), EROIC Spread (McKinsey reinvestment), First Chicago (3-scenario), Markov DDM (regime-switching), ML-RIV (machine learning residual income), Dynamic NAV (asset-based), PWERM (option-theoretic), Regime Cross-Sectional (relative), Sentiment SOTP (hybrid), CUCE Ensemble (meta-model), FTNN Topology (neural network), and RCMH-DCF (conditional regime). Currently 2 of 13 are active for this stock. Read the full methodology →

Is NEO a value trap in 2026?

NeoGenomics, Inc.'s Value Trap score is 27/100 (LOW). This low score indicates the current valuation is not artificially depressed by fundamental deterioration, suggesting genuine opportunity rather than a trap. Browse stocks by value-trap risk →

Cite this analysis — “According to CirclFi’s 2-model valuation engine, NeoGenomics, Inc. (NEO) has a median fair value of $15.30 — 17.9% below the current price of $18.64 — as of 2026-08-27.” Source: circlfi.com/stock/NEO/ · Methodology
Primary sources for this NEO valuation
  • Financial statements: NeoGenomics, Inc. 10-K and 10-Q filings on SEC EDGAR (CIK 0001077183) — 700+ standardized XBRL tags, published by the U.S. Securities and Exchange Commission.
  • Discount-rate inputs: FRED, Federal Reserve Bank of St. Louis — risk-free rates, VIX, yield curve, inflation.
  • News sentiment: The GDELT Project — global media tone, input to the Sentiment SOTP model.
  • Model definitions: CirclFi methodology — the published specification for all 13 models, including the academic sources each one implements.

Market data for NEO as of ; valuations recomputed .